VistaGen Therapeutics, Inc. Form 8-K May 02, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 2, 2019

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter)

NEVADA	001-37761	20-5093315
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

343 Allerton Ave.South San Francisco, California 94090 (Address of principal executive offices)

(650) 577-3600 (Registrant's telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging growth company []

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

Securities registered pursuant to Section 12(b) of the Act:

		Name of
	Trading Symbol	each
Title of each class		exchange
		on which
Common Stock, par value \$0.001 per share	VTGN	registered
		Nasdaq
		Capital
		Market

Item 7.01 Regulation FD Disclosure.

VistaGen Therapeutics, Inc. (the "Company") today began utilizing a new corporate presentation. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Items.

The Company today announced topline results from an exploratory clinical study of AV-101 as a monotherapy in patients with treatment-resistant depression ("TRD"). The 19-patient study was sponsored and conducted by the U.S National Institute of Mental Health ("NIMH"). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits Index

Exhibit No. Description

<u>99.1</u> Corporate Presentation, dated May 2, 2019

<u>99.2</u> Press Release issued by VistaGen Therapeutics, Inc., dated May 2, 2019.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

By:

Date: May 2, 2019

/s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Description

- Corporate Presentation, dated May 2, 2019
- <u>99.1</u> 99.2 Press Release issued by VistaGen Therapeutics, Inc., dated May 2, 2019.